Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cytokine
Main Authors: Cludts, Isabelle, Spinelli, Francesca Romana, Morello, Francesca, Hockley, Jason, Valesini, Guido, Wadhwa, Meenu
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science Ltd 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484178/
https://ncbi.nlm.nih.gov/pubmed/28279855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cyto.2017.02.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados